Our findings may provide new insights into the regulation of inflammatory responses during the pathogenic process of GBS and suggest that the levels of plasma and CSF IL-17A and IL-37 may be important for evaluating the disease severity and therapeutic efficacy in GBS patients. This evidence concerns the gene IL17A and Guillain-Barre syndrome.